Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTHi-Mcat vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The NTHi-Mcat vaccine (GSK3228836A) is an investigational protein subunit vaccine developed by GSK, specifically designed to prevent exacerbations in patients with chronic obstructive pulmonary disease (COPD). The vaccine targets two major bacterial pathogens associated with respiratory infections and COPD flare-ups: Non-typeable *Haemophilus influenzae* (NTHi) and *Moraxella catarrhalis* (Mcat). The formulation consists of four recombinant surface proteins: three from NTHi (Protein D, Protein E, and PilA) and one from Mcat (Ubiquitous surface protein A2, or UspA2). To enhance the immune response in the target population of older adults and smokers, the vaccine is formulated with GSK's proprietary AS01E adjuvant system, which contains the immunostimulants MPL (3-O-desacyl-4’-monophosphoryl lipid A) and QS-21 (*Quillaja saponaria* fraction 21) in a liposomal carrier.
- Other names
- NTHi-McatAS01E-adjuvanted NTHi-Mcat vaccineAS-01E-adjuvanted NTHi-Mcat vaccineAS 01E-adjuvanted NTHi-Mcat vaccineGSK NTHi-Mcat vaccine
02
Targets
UspA2PD (Protein D)PilA (Type IV pilus protein PilA)PE (Phosphatidylethanolamine)
Beyond the preview
Go deeper on NTHi-Mcat vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTHi-Mcat vaccine.